Mer­ck R&D chief Roger Perl­mut­ter of­fers some heavy­weight R&D glam to a lit­tle up­start biotech out to cure Duchenne MD

Back when Roger Perl­mut­ter jumped in­to a lead­ing role as R&D chief at Mer­ck, one of the first things he did was bow out of the round of board po­si­tions he had built up af­ter de­part­ing Am­gen.

It didn’t make any sense to di­vide his time, he tells me, un­til things qui­et­ed down at the phar­ma gi­ant, which has been spear­head­ing the rev­o­lu­tion in PD-1/L1 check­point in­hibitors with hun­dreds of on­go­ing stud­ies in­volv­ing Keytru­da.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER